Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA 15213, USA.
PM R. 2011 Jun;3(6 Suppl 1):S123-31. doi: 10.1016/j.pmrj.2011.03.012.
Cytidine 5'-diphosphocholine (CDP-choline or citicoline) is a highly bioavailable compound with potential benefits for aiding neural repair and increasing acetylcholine levels in the central and peripheral nervous system. As a result, many researchers have investigated the use of CDP-choline for various types of neurological insult or conditions, including stroke, traumatic brain injury, and Alzheimer disease. Despite the fact that the safety of the compound has been verified across multiple international studies, evidence for efficacy remains less clear. This may be attributable, at least in part, to several issues, including a lack of randomized clinical trials, a lack of availability of the compound in the United States, and statistical power issues in reported trials. In addition, the fact that CDP-choline has multiple potential points of therapeutic impact makes it an exciting treatment option in theory but also complicates the analysis of efficacy in the sense that multiple mechanisms and time points must be evaluated. Although some clinical conditions do not appear to benefit from CDP-choline treatment, the majority of findings to date have suggested at least minor benefits of treatment. In this review we will examine the evidence in the published literature pertaining to use of CDP-choline in rehabilitation populations and briefly consider the work yet to be done.
胞苷 5'-二磷酸胆碱（CDP-胆碱或胞磷胆碱）是一种具有高度生物利用度的化合物，具有促进神经修复和增加中枢及外周神经系统乙酰胆碱水平的潜力。因此，许多研究人员已经研究了 CDP-胆碱在各种类型的神经损伤或疾病中的应用，包括中风、外伤性脑损伤和阿尔茨海默病。尽管该化合物的安全性已在多项国际研究中得到验证，但疗效证据仍不够明确。这可能至少部分归因于以下几个问题，包括缺乏随机临床试验、该化合物在美国不可用以及报告试验中的统计效力问题。此外，CDP-胆碱具有多个潜在的治疗作用点，这使得它在理论上成为一种令人兴奋的治疗选择，但也使疗效分析变得复杂，因为必须评估多个机制和时间点。尽管某些临床病症似乎没有从 CDP-胆碱治疗中获益，但迄今为止的大多数研究结果表明，治疗至少有轻微益处。在这篇综述中，我们将检查已发表文献中关于 CDP-胆碱在康复人群中应用的证据，并简要考虑尚未完成的工作。
